Is It Worthwhile For Investors To Follow These Insider Trades On Mustang Bio Inc. (MBIO)?

0
9
KOSK
KOSK

Mustang Bio Inc. (NASDAQ:MBIO) traded with a subtraction of -$0.06 to $0.47 on Thursday, a downside of -11.72 percent. An average of 482,367 shares of common stock have been traded in the last five days. There was a fall of -$0.1134 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 341,522 shares traded, while the 50-day average volume stands at 617,595.

MBIO stock has decreased by -18.39% in the last month. The company shares reached their 1-month lowest point of $0.4429 on 09/22/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.51 and a high of $2.82 in 52 weeks. It has reached a new high 2 times so far this year and lost -67.92% or -$1.1891 in price. In spite of this, the price is down -83.31% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Insider Transactions

282 days have passed since Mustang Bio Inc. (MBIO) last reported insider trading activity. Achenbach Brian, who is SVP, Fin. & Corp. Controller, most recently acquired $4,374 shares at $1.83 per share on Dec 14. In this transaction, the insider spent $8,004. SVP, Fin. & Corp. Controller, Achenbach Brian, disposed of 4,450 shares at a price of $2.28 on Oct 12. The insider now owns more than $10,146 worth of shares.

Valuation Metrics

Mustang Bio Inc. (MBIO) stock’s beta is 1.58. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.67.

Financial Health

The quick ratio of Mustang Bio Inc. for the three months ended June 29 was 10.00, and the current ratio was 10.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.33 and a total debt to equity ratio of 0.33 for the quarter ending June 29. Its gross profit as reported stood at $15000.0 compared to revenue of $66.72 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Mustang Bio Inc.’s return on assets was -58.60%.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$24.46 million in the quarter, while revenues of -$14.36 million were grew 40.31%. The analyst consensus anticipated Mustang Bio Inc.’s latest quarter earnings to come in at -$0.21 per share, but it turned out to be -$0.19, a 9.50% surprise. For the quarter, EBITDA amounted to -$17.38 million. Shareholders own equity worth $106.07 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Mustang Bio Inc. (MBIO) price momentum. RSI 9-day as of the close on 21 September was 18.94%, suggesting the stock is oversold, with historical volatility in this time frame at 60.50%.

As of today, MBIO’s price is $0.5270 -19.41% or -$0.1134 from its 5-day moving average. MBIO is currently trading -32.73% lower than its 20-day SMA and -36.77% lower than its 100-day SMA. However, the stock’s current price level is -25.16% below the SMA50 and -75.73% below the SMA200.

The stochastic %K and %D were 8.98% and 6.34%, respectively, and the average true range (ATR) was 0.0533. With the 14-day stochastic at 14.21% and the average true range at 0.0540, the RSI (14) stands at 26.91%. The stock has reached -0.0499 on the 9-day MACD Oscillator while the 14-day reading was at -0.0663.

Analyst Ratings

BTIG Research launched coverage on Mustang Bio Inc. (NASDAQ: MBIO) in its analyst report released on May 18, 2021. The firm assigned the stock a Buy rating.

LEAVE A REPLY

Please enter your comment!
Please enter your name here